WO2009091435A2 - Procédés d'inhibition d'une infection virale - Google Patents

Procédés d'inhibition d'une infection virale Download PDF

Info

Publication number
WO2009091435A2
WO2009091435A2 PCT/US2008/081904 US2008081904W WO2009091435A2 WO 2009091435 A2 WO2009091435 A2 WO 2009091435A2 US 2008081904 W US2008081904 W US 2008081904W WO 2009091435 A2 WO2009091435 A2 WO 2009091435A2
Authority
WO
WIPO (PCT)
Prior art keywords
virus
compound
compounds
viruses
cell
Prior art date
Application number
PCT/US2008/081904
Other languages
English (en)
Other versions
WO2009091435A3 (fr
Inventor
Michael Kinch
Michael Goldblatt
Original Assignee
Functional Genetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Functional Genetics, Inc. filed Critical Functional Genetics, Inc.
Priority to NZ584850A priority Critical patent/NZ584850A/en
Priority to EP08870586A priority patent/EP2203065A4/fr
Priority to CN200880114145A priority patent/CN101842014A/zh
Priority to CA2701492A priority patent/CA2701492A1/fr
Priority to MX2010004406A priority patent/MX2010004406A/es
Priority to JP2010532262A priority patent/JP2011502168A/ja
Priority to AU2008348158A priority patent/AU2008348158A1/en
Publication of WO2009091435A2 publication Critical patent/WO2009091435A2/fr
Publication of WO2009091435A3 publication Critical patent/WO2009091435A3/fr
Priority to ZA2010/02351A priority patent/ZA201002351B/en
Priority to IL204940A priority patent/IL204940A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Definitions

  • viruses vary markedly in structure, life cycle, susceptible cells and animal targets, and the like. Many times, a vaccination or treatment method to limit or inhibit viral infection is time limited - a first generation of virus may be effectively inhibited, only to have a mutated strain break any protection conferred by an earlier vaccine or therapy.
  • 2006-0142259 Al the entirety of which is incorporated by reference includes a set of compounds that were found to have activity in blocking TSGlOl binding to the PTAP domain found in the HIV p6 Gag protein. Given the role of TSGlOl in HIV infectivity, these compounds were indicated to have potential therapeutic utility for HIV/AIDS, as reflected by in vitro testing.
  • the compound tested had the chemical name, as set forth in the reports, 4'-chloro-5-[(7-chloro-4- quinolinyl)amino]-3-(l,l-dimethylethylamino)methyl [l,l'-biphenyl]-2-ol dihydrochloride.
  • the compound was administered as a salt in dosage values of from 9 - 1250 mg (as a salt)/kg of body weight.
  • Mammalian models used were dogs, rabbits, mice, and rats.
  • FGI- 104 compounds are designated as lead compounds designated as Rl 9 and R24. These compounds were generated based on predicted inhibition of TSGlOl. While the activity of these molecules may not necessarily involve or be limited to TSGlOl as a target, data generated does indicate that the FGI- 104 compounds appear to inhibit viral activity by blocking late stage viral activity, possibly after completion of viral protein synthesis. This would be consistent with targeting TSGlOl, as interfering/inhibiting the interaction of the viral particles and this protein could interfere with travel by the virus to the cell surface and subsequent budding.
  • Compounds of particular interest include compounds Rl 9, R24. Collectively, this family of compounds is referred to herein as FGI- 104 compounds. The chemical formulae of compounds R19 and R24 are given in Figures 1-2.
  • Figure 1 sets forth the Chemical Structure, Molecular Formula and IUPAC name, as well as pertinent physico-chemical properties of one of the active compounds that is the subject of this invention, Rl 9.
  • Figure 2 sets forth the Chemical Structure, Molecular Formula and IUPAC name, as well as pertinent physico-chemical properties one of the active compounds that is the subject of this invention, R24.
  • Figure 3 presents the activity of Rl 9 and R24 against infection challenge, in vitro, against HIV.
  • Figure 4 presents the activity of Rl 9 and R24 against infection challenge, in vitro, against Influenza.
  • Figure 5 presents the activity of Rl 9 and R24 against infection challenge, in vitro, against Hepatitis viruses (HBV, HCV 1, HCV 2).
  • Figure 6 presents the activity of Rl 9 and R24 against infection challenge, in vitro, against PRRS Virus, a viral infection most commonly found in pigs.
  • Figure 7 provides a common chemical structure for compounds of this family showing antiviral activity
  • Figures 8 A - 80 depict various members of the family of small molecules of FGI- 104.
  • Figures 9A and 9B present, in tabular form, the CC50 and inhibitory dosage of the members of the FGI- 104 family shown in Figures 8A - 8P when measured against a single virus - porcine reproductive and respiratory syndrome (PRRS) virus, a commercially critical virus that devastates pig stocks worldwide.
  • PRRS porcine reproductive and respiratory syndrome
  • Figure 10 presents in capsule form one of the lead compounds of the FGI- 104 chemical family, as well as its fundamental properties at a glance.
  • Figure 11 presents, in tabular form, pertinent information as to the EC50 and CC50 for R24 when tested against a number of different viruses drawn from very different families.
  • Figure 12 presents, in graph and table form, information regarding the inhibition of a pox virus by R24 in cell based assays.
  • Figure 13 provides data in the form of a graph, table and protein blot confirming the inhibition of Hepatitis C virus by R24.
  • Figure 14 provides by table and graph information reflecting the inhibition of Hepatitis B virus by R24.
  • Figure 15 provides further information on PRRS virus inhibition by R24 in table form.
  • Figure 16 provides a bar graph reflecting data showing the inhibition of influenza virus by R24.
  • Figure 17 provides information by graph and table demonstrating the inhibition of Ebola hemorrhagic virus by R24.
  • Figure 18 addresses inhibition of Venezuelan Equine Encephalomyelitis (VEE), an alpha virus, by R24.
  • VEE Venezuelan Equine Encephalomyelitis
  • Figure 20 demonstrates, by comparing R24 inhibition of HBV in a viral release assay, and a replicon suppression assay, that R24 activity is present in the later stages of the viral cycle.
  • Figure 21 presents in Table form information demonstrating R24 is not toxic to cells.
  • Figure 22 presents in table and bullet point format certain information obtained from earlier studies on R24, demonstrating its safety for mammalian use.
  • Figure 23 presents the chemical name, structure and physiochemical properties of lead compound R24.
  • Figure 24 presents a simple synthesis scheme for lead compound R24 consistent with good laboratory practice.
  • Figure 25 presents data on the efficiency and scalability of the synthesis scheme of Figure 24.
  • Figure 26 presents in table form the solubility of R24 in various pharmaceutically oriented solvent systems.
  • the family of FGI- 104 compounds was developed by computer design to identify compounds that would interfere with late stage (in the virus maturation cycle) binding between TSGlOl and target viruses.
  • TSG is known to bind with the PTAP motif of HIV.
  • Compounds designed to fit and occupy the TSGlOl binding site would have a reasonable expectation of preventing the binding between TSGlOl and target viruses.
  • transport by TSGlOl and related proteins of the EXCRT or ESCRT-I complex have been shown to be a prerequisite to migration to the cell surface, maturation and budding. Without the TSGlOl binding event, the expectation was that viral reproduction and spread of infection would be inhibited.
  • Figure 3 demonstrates the effectiveness of these two compounds in the inhibition, in a dose dependent relationship, of one of the most thoroughly researched of viral diseases, HIV.
  • Activity is shown as the amount of luciferase detected. In the absence of luciferase signal, there is no viral activity).
  • Both of these compounds, at relatively mild dosages, showed complete inhibition of HIV.
  • These same compounds have been shown to be effective in providing protection against infection challenge in in vitro studies against a wide variety of viral agents, including HIV, influenza, HBV, HCV, Punta Toro virus, and PRRS virus as shown in Figures 3-6.
  • the design of the compounds of FGI-104 allows the provision of a neat compound structure for which activity can be provided. As is always the case, given the variation in species, viruses and individuals, not all FGI-104 compounds will show the same degree of activity in inhibiting all viruses in all mammalian species. Given the data provided, however, one can reasonably expect a compound drawn from the general formula of Figure 7 will provide a mammalian host at least some protection against viral infection at a dosage value of 1 ng - 250 mg/kg of host body weight. Within that range, those of skill in the art are well acquainted with titration analysis to arrive at an optimum dosage given a specific host and virus. See, e.g., "Remington: The Science and Practice of Pharmacy," University of the Sciences in Philadelphia, 21st ed., Mack Publishing Co., (2005), the disclosure of which is hereby incorporated by reference in its entirety.
  • the invention of this application is not limited to the inhibition of viral infections in human, nor to any specific compound.
  • Two viruses that infest commercial mammals are PRRS Virus, and Bovine Corona virus, which devastate pig and cow populations around the world. The pig is perhaps the world's most important non-human commercial mammal.
  • the effectiveness of sixteen of the tested FGI- 104 compounds against PRRS Virus, Bovine Corona virus, the testing being set forth in Figures 3-6 and 9, allows the identification of a variety of viruses against which the FGI- 104 compounds may be expected to demonstrate inhibition. This list is not exhaustive, and to date, no virus has been identified which escapes the effects of all members of the FGI- 104 family. But among prominent viruses which are important either from a human or animal health viewpoint are those such as influenza and PRRS, and viruses which present bioterrorism threats, such as Ebola, Marburg and other hemorrhagic fever viruses.
  • viruses Among the multiple viruses whose infection may be treated by administration of FGI- 104 compounds are certain families of viruses, including Group IV viruses (as demonstrated by activity against hepatitis C viruses); Group V viruses (as demonstrated by activity against influenza viruses); Group VI (represented by HIV virus) and Group VII (as demonstrated by activity against hepatitis B viruses).
  • Group I viruses possess double-stranded DNA and include such virus families as Herpesviridae (examples like HSVl (oral herpes), HSV2 (genital herpes), VZV (chickenpox), EBV (Epstein-Barr virus), CMV (Cytomegalovirus), Poxviridae (smallpox) and many tailed bacteriophages.
  • the mimivirus was also placed into this group.
  • Group II viruses possess single-stranded DNA and include such virus families as Parvoviridae and the important bacteriophage Ml 3.
  • Herpes Simplex Virus Varicella zoster virus
  • RNA viruses [0045] Group III: viruses possess double-stranded RNA genomes, e.g. rotavirus. These genomes are always segmented.
  • Group IV viruses possess positive-sense single-stranded RNA genomes. Many well known viruses are found in this group, including the picornaviruses (which is a family of viruses that includes well-known viruses like Hepatitis A virus, enteroviruses, rhinoviruses, poliovirus, and foot-and-mouth virus), SARS virus, hepatitis C virus, yellow fever virus, and rubella virus.
  • picornaviruses which is a family of viruses that includes well-known viruses like Hepatitis A virus, enteroviruses, rhinoviruses, poliovirus, and foot-and-mouth virus
  • SARS virus hepatitis C virus
  • yellow fever virus yellow fever virus
  • rubella virus rubella virus
  • Group V viruses possess negative-sense single-stranded RNA genomes.
  • the deadly Ebola and Marburg viruses are well known members of this group, along with influenza virus, measles, mumps and rabies.
  • Group VI viruses possess single-stranded RNA genomes and replicate using reverse transcriptase.
  • the retroviruses are included in this group, of which HIV is a member.
  • Group VII viruses possess double-stranded DNA genomes and replicate using reverse transcriptase.
  • the hepatitis B virus can be found in this group.
  • viruses discussed above are grouped largely in terms of human infection.
  • the FGI- 104 compounds are effective in disrupting or interfering with the host mechanisms necessary for viral propagation that are highly conserved among mammalian or eukaryotic species. Consequently, these compounds could have application for human or veterinary viral diseases.
  • These viral diseases could include but are not limited to PRRS virus, porcine or bovine circoviruses, porcine or bovine corona viruses, porcine or bovine RSV, porcine or bovine influenza, EIAV, bluetongue, or foot and mouth disease (FMD) viruses.
  • Some viruses are causative of more chronic diseases and the morbidity or mortality relates to the presence of virus. These diseases include hepatocellular carcinoma (associated with either HBV or HCV), chronic fatigue syndrome (associated with EBV) and other diseases linked with viral infection. As the compounds of the FGI- 104 family have proven effective in inhibiting or treating these viruses, the administration of these compounds, in vivo, should provide a method of controlling and relieving these chronic conditions and the associated morbidity.
  • the compounds above could be used for the treatment or prevention (prophylaxis) of single viral pathogens (e.g., HIV or HBV) or combinations thereof (HIV and HBV).
  • single viral pathogens e.g., HIV or HBV
  • HIV and HBV combinations thereof
  • these individual or broad-spectrum applications could entail any or all of the virus groups detailed above.
  • Another method could be the use of the compounds for certain indications associated with one or more viruses.
  • these compounds could be used for the prevention or treatment of respiratory virus infections, which can be caused by one or more of the pathogens from the groups identified above.
  • these compounds could have application against one or more blood-borne pathogens (e.g., HIV and/or HBV and HCV).
  • the compounds could have application for the prevention, treatment, or maintenance of acute or chronic viruses.
  • Acute applications include short-term prevention or treatment of viral infection, examples of which include influenza, rotavirus or filovirus infection.
  • Chronic applications could include recurrent outbreaks, (such as is observed with genital herpes) or infrequent outbreaks (such as those associated with zoster infection during shingles).
  • treatment could be intended over the long term to maintain low levels of viral load for chronic virus infection (e.g., for HIV, HBV or HCV treatment).
  • Treatment in the context of this application for patent, and this invention, embraces both prophylaxis and therapeutic administration.
  • Administration of the FGI- 104 compounds at or before the "challenge" of a virus should provide a means of inhibiting or reducing infection in those likely to encounter the virus, such as service people or others dispatched to areas where viruses are found against which they might have little or no natural resistance, such as Ebola virus.
  • Treatment can be after infection. Indeed, research suggests that days after infection, administration of FGI- 104 compounds may be effective in arresting and/or reversing the course of viral infection. Treatment also embraces extending the survivability of the infected subject, so that the body's natural defense mechanisms can combat and overwhelm the viral infection, and reducing the level of viral infection.
  • the compounds could be used alone or in combination with the current standards of care for any of the viruses indicated above.
  • oral, cutaneous, subcutaneous, suppository, IV or IM injection, or sustained IV administration are preferred routes.
  • Dosages will vary from mammal to mammal and virus to virus.
  • 0.001 mg/kilo/day - 200 mg/kilo/day, IV are target dosages.
  • the FGI- 104 compounds have been demonstrated to exhibit robust activity in animal models of otherwise deadly viruses (Ebola, Marburg) that doses in the range of 0.1-10 mg/kg, delivered once pre- or post-infection, are sufficient to prevent virus-mediated death.
  • Those of skill in the art are well equipped by conventional protocols, given the identification of targets and compounds herein, to identify specific dosages for specific mammals, specific viruses, and specific modes of administration.
  • Rl 9 and R24 are representative only. Variations and derivations of the core parental compounds are one aspect of the invention.
  • an oxime or methoxyamine derivative of the parent compound could provide an opportunity for oral delivery.
  • the advantages of oral delivery can include ease of administration, patient compliance and/or distribution and reimbursement.
  • a representative core structure, with substituents, embracing the most active compounds, is set forth in Figure 7.
  • Each substituent X is independently H or an electron donating group, which may be selected from the group including chloro or other halogen, alkoxy (--OR), hydroxyl (—OH); aryloxy (-OAr), trialkylammonium (-NR 3 +), alkylamido (-NHCOR, -NRCOR), arylamido (-NHCOAr, -NRCOAr, -NArCOAr), arylcarbamoyl (-NHCOOAr, - NRCOOAr), alkylcarbamoyl (-NHC00R, -NRCOOR'), cyano (-CN), nitro (-NO 2 ), ester (-C00R, -COOAr), or alkyl halo.
  • Each substituent Y is independently H, alkyl of 1 - 4 carbon atoms, hydroxy, alkoxy or methylene.
  • Substituent Z is a di-or-tri akly amino, or alkyl di or tri amino, optionally substituted with a halogen moiety.
  • the FGI- 104 family of compounds includes a large number of variations. Different compounds will have different activities against different viruses, as reflected by the data set forth in Figures 9A - 9C. It is not practical or desirable to test all active compounds of this family against all viruses, or even a sampling.
  • R24 is effective against HBV, as set forth in Figure 14. Although dilution of the sample stock "foxed" actual stock, giving a relatively falsely low but comfortable Safety Index of more than 130, the primary assay run for R24 against HBV using HepG2 cells showed a high level of activity, as measured by virion DNA. These results were obtained from blinded studies conducted by the National Institute for Allergies and Infectious Diseases, further reaffirming the reliability and accuracy of the data presented in Figure 14.
  • PRRS virus As noted above, important mammalian hosts treatable by this family of compounds include not only humans, but veterinarily and commercially important animals. Although monkeys, dogs, cats, mice, rats, horses, rabbits, cattle, sheep and goats are all important hosts to be treated for viral infection, pigs may be the dominant commercial animal, worldwide.
  • the United States Department of Agriculture has characterized PRRS virus as a significant, worldwide, agricultural concern related to animal health and causes large economic losses to producers, and labeled a biosecurity threat. (Project 2008-2017).
  • Figure 15 demonstrates the effectiveness of R24 in inhibiting PRRS, where the host is the virus's natural target, primary porcine lung alveolar macrophages.
  • R24 is also effective against viruses that infect both animals and humans with wide activity. Influenza kills thirty thousand people in the United States every year, and is endemic worldwide. Complicating matters is the fact that various serotypes and strains of the virus often are not protected by a single vaccine. Those most in need of protection, the elderly and those immunologically challenged, frequently benefit least from the vaccine. As shown in Figure 16, R24 and the other compounds of the FGI- 104 family are remarkably effective in inhibiting influenza viral activity, this time in a MDCK cell-based assay. Clearly, by targeting interaction between a host protein, TSGlOl, and viruses in general, R24, and the FGI-104 compounds, are effective against a wide distribution of viruses, exhibiting potent activity with little safety risk.
  • Alphaviruses like Venezuelan Equine Encephalomyelitis, constitute yet another class of viruses that infect both humans and mammalian animals like horses and cows.
  • an outbreak in South America killed an estimated 20,000 people and huge numbers of animals.
  • R24 provided dramatic inhibition of VEE at levels of 25 uM, again administered 3 days post-infection.
  • rubella German measles.
  • HIV has a different viral maturation cycle than most viruses. It has also proved adept in evading most agents, biological and chemical, targeted at the virus, or the effects of the virus, itself. More resources have been devoted to finding a treatment or preventive agent for HIV than any other virus. Yet, treatment of this virus remains elusive.
  • Figure 19 the results of R24 administration to MT-4 cells infected with HIV are shown by graph and in table format. As shown (increasing dosage runs from right to left) in a dose response fashion, R24 inhibits HIV-I activity, dropping the luciferase detection to effective zero at a relatively low dose, when administered 72 hours post infection (MT-4 cells). The compound is well tolerated, and gives a Safety Index of 16 with an EC50 value of 8.5 uM.
  • R24 like the family of FGI- 104 compounds, was targeted to interfere with the interaction between viruses and TSGlOl, giving the compound a greater range of viral inhibition than most virus targeted agents. Confirmation that the agents work to interfere with, and thus treat, viral infection comes from the assays shown in Figure 20, which contrasts the effectiveness in suppressing viral release of HBV and HCV from Huhl cells, and replicon formation. As shown, R24 does little to inhibit replicon formation, but is effective in preventing viral release. This strongly suggests that the interaction or activity of R24 occurs after viral protein synthesis is complete (thus replicon formation) but before complete maturation and release.
  • R24 is subject to straight forward synthesis. Specific important physical and chemical information is presented in Figure 23. While the compound exhibits instability to light, R24 is easily protected from light, whether present as a solid, or prepared in a solution or suspension for administration. The range of carriers available, is therefore, quite large. As a consequence, the compositions and methods of this invention embrace the FGI- 104 compounds as neat solids, as pharmaceutically suitable preparations, in a pharmaceutically acceptable carrier of a variety of types.
  • compositions of the present invention may further comprise a pharmaceutical composition comprising a therapeutically effective amount of any of the small molecules (or combinations of small molecules) described above together with other materials, such as a suitable carrier, excipients, etc., for administration to a human or animal experiencing a viral infection or at risk of a viral infection.
  • Such pharmaceutical compositions may be in solid, gel or liquid form and may be administered as appropriate to an individual IV, IM, IP or parenterally, topically, subcutaneous Iy, orally, or through mucosal surfaces and routes (including, for example, rectal and vaginal suppositories).
  • the exact dosage corresponding to a therapeutically effective amount will vary from mammal to mammal and virus to virus.
  • the FGI- 104 compounds may be administered as the sole active agent administered, either prophylactically or therapeutically, or together with other active agents.
  • the other active agents may be other anti-viral agents, it is envisaged that the FGI- 104 compounds may be administered together with agents targeted at secondary effects of the viral infection or associated chronic diseases, or for example, an anti-bacterial agent.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés, des compositions pharmaceutiques et des procédés d'inhibition d'une infection virale chez un mammifère en ayant besoin. Ceux-ci font appel à des composés de la formule (I), dans laquelle chaque X représente indépendamment un atome H ou un groupe électrodonneur, chaque Y représente indépendamment un atome H, un groupe alkyle de 1 à 4 atomes de carbone, hydroxy, alcoxy ou méthylène et dans laquelle le substituant Z est un groupe di- ou trialkylamino, ou un groupe alkyle di- ou triamino, éventuellement substitué par une fraction halogène. Cette famille de composés, désignée par FGI-104, inhibe une infection virale de manière thérapeutique ou prophylactique.
PCT/US2008/081904 2007-10-31 2008-10-31 Procédés d'inhibition d'une infection virale WO2009091435A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ584850A NZ584850A (en) 2007-10-31 2008-10-31 Methods of inhibiting viral infection
EP08870586A EP2203065A4 (fr) 2007-10-31 2008-10-31 Procédés d'inhibition d'une infection virale
CN200880114145A CN101842014A (zh) 2007-10-31 2008-10-31 抑制病毒感染的方法
CA2701492A CA2701492A1 (fr) 2007-10-31 2008-10-31 Procedes d'inhibition d'une infection virale
MX2010004406A MX2010004406A (es) 2007-10-31 2008-10-31 Metodos para inhibir infeccion viral.
JP2010532262A JP2011502168A (ja) 2007-10-31 2008-10-31 ウイルス感染の阻害方法
AU2008348158A AU2008348158A1 (en) 2007-10-31 2008-10-31 Methods of inhibiting viral infection
ZA2010/02351A ZA201002351B (en) 2007-10-31 2010-04-01 Methods of inhibiting viral infection
IL204940A IL204940A0 (en) 2007-10-31 2010-04-08 Methods of inhibiting viral infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98396607P 2007-10-31 2007-10-31
US60/983,966 2007-10-31

Publications (2)

Publication Number Publication Date
WO2009091435A2 true WO2009091435A2 (fr) 2009-07-23
WO2009091435A3 WO2009091435A3 (fr) 2009-10-15

Family

ID=40885845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/081904 WO2009091435A2 (fr) 2007-10-31 2008-10-31 Procédés d'inhibition d'une infection virale

Country Status (11)

Country Link
US (1) US20120142731A1 (fr)
EP (1) EP2203065A4 (fr)
JP (1) JP2011502168A (fr)
CN (1) CN101842014A (fr)
AU (1) AU2008348158A1 (fr)
CA (1) CA2701492A1 (fr)
IL (1) IL204940A0 (fr)
MX (1) MX2010004406A (fr)
NZ (1) NZ584850A (fr)
WO (1) WO2009091435A2 (fr)
ZA (1) ZA201002351B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102205A4 (fr) * 2014-02-06 2017-07-26 Georgetown University Traitement d'infections par un flavivirus avec de l'amodiaquine et ses dérivés

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220411378A1 (en) * 2019-11-15 2022-12-29 Georgia State University Research Foundation, Inc. Small molecules polymerase inhibitors
WO2023212718A2 (fr) * 2022-04-29 2023-11-02 Cornell University Procédés de traitement d'une infection virale et procédés d'inhibition de réplication virale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304554A (en) * 1990-04-27 1994-04-19 Emory University 4-[(alkyl or dialkyl)amino]quinolines and their method of preparation
US8021833B2 (en) * 2003-02-12 2011-09-20 Functional Genetics, Inc. Method for reducing HIV viral budding by administering a VPS28-specfic antibody that disrupts Gag-TSG101-VPS28 binding interactions
EP1874116A4 (fr) * 2004-06-25 2008-05-28 Functional Genetics Inc Composés, compositions pharmaceutiques et procédés pour inhiber l"infectivité hiv
EP1846401B1 (fr) * 2005-02-04 2008-06-18 CTG Pharma S.r.l. Nouveaux dérivés de 4-aminoquinoléine comme composés antimalaria
GB0507672D0 (en) * 2005-04-15 2005-05-25 Barnaba Vincenzo Adjuvant

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2203065A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3102205A4 (fr) * 2014-02-06 2017-07-26 Georgetown University Traitement d'infections par un flavivirus avec de l'amodiaquine et ses dérivés

Also Published As

Publication number Publication date
CA2701492A1 (fr) 2009-07-23
NZ584850A (en) 2012-02-24
JP2011502168A (ja) 2011-01-20
CN101842014A (zh) 2010-09-22
EP2203065A2 (fr) 2010-07-07
US20120142731A1 (en) 2012-06-07
IL204940A0 (en) 2010-11-30
EP2203065A4 (fr) 2012-02-29
WO2009091435A3 (fr) 2009-10-15
AU2008348158A1 (en) 2009-07-23
ZA201002351B (en) 2011-06-29
MX2010004406A (es) 2010-05-17

Similar Documents

Publication Publication Date Title
Berhanu et al. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation
CN111233650B (zh) 一种抗病毒的蒽醌衍生物及其应用
DK2893936T3 (en) Glutaryl histamine for the treatment and prevention of diseases caused by (+) - RNA-containing viruses
Ikeda et al. In vitro and in vivo inhibition of ortho-and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion
Hao et al. Acyclovir inhibits channel catfish virus replication and protects channel catfish ovary cells from apoptosis
WO2009091435A2 (fr) Procédés d'inhibition d'une infection virale
Sauter et al. Evolutionary conflicts and adverse effects of antiviral factors
Ghaseminia Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination
Hurtado et al. Antiviral activity of lauryl gallate against animal viruses
JP2023518390A (ja) ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物
US8207209B2 (en) Methods of inhibiting viral infection
Allen et al. Target-organ treatment of neurotropic virus disease with interferon inducers
CN113197886A (zh) 双黄连制剂在抗病毒感染中的应用
Haider et al. The Pathophysiology of Repurposed Antiviral Drugs for treatment of COVID-19 Infection
Bray Viral bioterrorism and antiviral countermeasures
RU2805806C1 (ru) Способ профилактики респираторных вирусных инфекций (гриппа)
US20240100146A1 (en) Neuraminidase-Inhibited Influenza Virus
Vashi et al. Niclosamide inhibits Newcastle disease virus replication in chickens by perturbing the cellular glycolysis
CN103655550A (zh) Myrtucommuacetalone在治疗肾综合征出血热药物中的应用
Vinod A REVIEW ON THE DEVELOPMENT OF FAVIPRAVIR AGAINST SARS COV 2 INFECTION
CN103520171B (zh) Kadcoccitones A在制备治疗肾综合征出血热药物中的应用
CN103462995A (zh) Neonectrolide A在制备治疗肾综合征出血热药物中的应用
CN114848616A (zh) 枯茗醛在制备白斑综合症病毒抑制剂方面的应用
CN103585155A (zh) Trigolutesins A在治疗肾综合征出血热药物中的应用
Naik In silico evaluation of various anti-viral drugs for their efficiency against multiple SARS CoV-2 drug targets

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114145.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08870586

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2701492

Country of ref document: CA

Ref document number: 2008870586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008348158

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 204940

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2686/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/004406

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 584850

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010532262

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008348158

Country of ref document: AU

Date of ref document: 20081031

Kind code of ref document: A